Trials / Completed
CompletedNCT01305954
Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients
LCCC 1027: Expression Of P16INK4a As A Predictor Of Myelosuppression In Patients With Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- UNC Lineberger Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to measure the association between baseline expression of the senescence effector protein p16INK4a and myelosuppression due to chemotherapy in patients with breast cancer. Patients with Stage I-IV breast cancer will be included and myelosuppression will be assessed after the first cycle of chemotherapy via measurement of an absolute neutrophil count (ANC) measured one time between days 7-11 post cycle one. Study subjects will also be asked to complete a brief health behaviors questionnaire to gather information on other relevant variables.
Conditions
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2014-04-03
- Completion
- 2023-09-25
- First posted
- 2011-03-01
- Last updated
- 2024-09-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01305954. Inclusion in this directory is not an endorsement.